IL-4/IL-13 Fusion Polypeptides for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective solutions for inhibiting the biological activities of IL-4 and IL-13, which are key cytokines involved in various inflammatory and allergic conditions such as asthma, with existing treatments often having limitations in specificity and efficacy.
Innovation Solution
Development of IL-4/IL-13-specific fusion polypeptides that combine modified IL-4Rα and IL-13Rα components, engineered to form a fusion protein capable of specifically binding and inhibiting IL-4 and IL-13 with high affinity, thereby blocking their biological activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to inhibit IL-4 and IL-13 activities, then treatment coverage is provided, but specificity and efficacy are insufficient
Solution Approach 1:
The fusion polypeptide combines IL-4Rα and IL-13Rα components into a single molecule that can bind both IL-4 and IL-13 cytokines, providing multi-functional activity. This allows one therapeutic agent to address multiple cytokine-mediated pathways involved in inflammatory and allergic conditions, thereby improving treatment coverage while maintaining high specificity through targeted receptor-cytokine interactions
Solution Approach 2:
The invention creates a composite therapeutic molecule by fusing two distinct receptor components (IL-4Rα and IL-13Rα) into a single polypeptide structure. This composite construction enables simultaneous or differential binding to both IL-4 and IL-13, achieving broad efficacy against multiple cytokines while the engineered specificity ensures targeted action only on intended cytokine-receptor pairs
2Reliability
If fusion polypeptides are engineered to bind both IL-4 and IL-13, then efficacy is improved, but device complexity increases
Solution Approach 1:
The invention merges two separate receptor components (IL-4Rα and IL-13Rα) into a single fusion polypeptide molecule. This combining approach consolidates what would otherwise require two separate therapeutic agents into one molecule, improving efficacy through dual cytokine binding capability while the fused structure actually reduces administrative complexity compared to sequential or combination therapy regimens
Solution Approach 2:
The fusion polypeptide is designed with multi-functional capability to bind both IL-4 and IL-13 cytokines through its composite receptor structure. This universality allows a single therapeutic agent to address multiple pathological pathways, improving overall efficacy while simplifying the therapeutic regimen from multiple agents to one
Data Source
AI summary
Polypeptides and multimeric polypeptides capable of binding interleukin-4 (IL-4) and interluekin-13 (IL-13) which are useful therapeutically in methods of treating IL-4 and IL-13-related conditions or diseases.